Citations

Clear

20 citation(s) found for "Sloan, Anthony R".

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Sievers, Quinlan , Lu, Hao , Cool, Allison , Gajewski, Stefan , Kong, Tim , Noviski, Mark , Whelan, Sarah , Wang, Yuhan , Navarrete, Lizbeth Mendoza, Mi, Xiaoli , Mukerji, Ratul , Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Tan, Y. , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya‐Wen , Elechko, Jennifer, Phelps, Christopher B., Sekeres, Samantha, Bravo, Eduardo , Alencar, Alvaro J. , Islam, Prioty , Mato, Anthony R. , Noviski, Mark A , Wang, Yuhan , Mendoza Navarrete, Lizbeth , Ficici, Emel , Mukerji, Ratul , Iuliano, James N , Ye, Jordan , Sanchez Garcia De Los Rios, Mateo , Bousquet, Hugo , Tan, May , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya-Wen , Elechko, Jennifer , Maron, Maxim I , Phelps, Christopher B , Rahman, Jahan , Notti, Ryan Q , Sekeres, Samantha , Lamkin, Erica N , Bravo, Eduardo , Alencar, Alvaro J , Ewalt, Mark D , Islam, Prioty , Mato, Anthony , Roeker, Lindsey , Bhatt, Shruti , Taylor, Justin , Thompson, Meghan C , Hansen, Gwenn M , Abdel-Wahab, Omar , Lamkin, Erica , Ewalt, Mark D. , Roeker, Lindsey E. , Abdel‐Wahab, Omar

Mayo Clinic

Cancer Discovery | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2159-8290.cd-26-0251 | PMID 42484277 Get It

Abstract Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. Here we sequenced serial CLL samples from patients enrolled in the phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTK A428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTK A428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTK A428D exhibited a competitive disadvantage. A crystal structure of BTK A428D revealed that the mutant aspartate clashes with the adenine ring of ATP and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTK A428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling
Sloan, Anthony , Bukenya, George, Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair, Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Lohoff, Falk W. , Goodman, Wendy A., Miller, Tyler E., O’Connor, Christine M. , Lathia, Justin D. , Sloan, Anthony R , Luo, Jingqin , Rubin, Joshua B , Stavrou, Evi X , O'Connor, Christine M , Cameron, Scott J , Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair , Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Stavrou, Evi X. , Goodman, Wendy A., Miller, Tyler E., Nieman, Marvin T. , Sangwan, Naseer , Chan, Timothy An-thy , Khorana, Alok A. , Dhawan, Andrew , Cameron, Scott J.

Mayo Clinic

No container title available | August 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.06.668464 | PMID 41959130 Get It

Abstract Sex differences in cancer outcome, including that of glioblastoma (GBM), are shaped by biological, hormonal, and immunological factors and impact disease progression, treatment responses, survival, and tumor microenvironment (TME) interactions. Platelets regulate the immune responses and tumor progression in many cancers, but it is not clear how they contribute to these sex-based differences by affecting the dynamics of the TME. Here, we show that GBM patients exhibit heightened platelet reactivity driven by PAR4 signaling. In murine GBM models, both pharmacological inhibition of PAR4 using BMS986120 and genetic deletion of PAR4 significantly prolong survival in females but not males. This survival advantage is estrogen dependent: it is preserved in chromosomal male-hormonal female mice within the four-core genotype model and is rescued in ovariectomized mice treated with estrogen. The survival benefit is TME specific and is mediated by platelet-driven enhancement of CD8⁺ T cell infiltration into the tumor. Inhibition of platelet PAR4 signaling increases calcium signaling through an estrogen-dependent interaction between PAR4 and estrogen receptor β (ERβ)—a receptor interaction not previously described. PAR4-activated platelets within the TME suppress CD8⁺ T cell function, and depletion of CD8⁺ T cells abolishes both the tumor-induced platelet reactivity and the survival benefit conferred by PAR4 inhibition. These findings establish platelet-mediated PAR4 signaling as a critical driver of tumor progression and identify sex-specific immune responses as key to therapeutic efficacy.
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Kang, Bianca Y. , Cohen, Joel L. , Geronemus, Roy G. , Kilmer, Suzanne L. , Ross, E. Victor , Tanzi, Elizabeth L., Waibel, Jill , Alam, Murad, Alexiades, Macrene , Arndt, Kenneth A., Avram, Mathew M., Biesman, Brian S. , Bloom, Jason D. , Burns, A. Jay, DiGiorgio, Catherine M., Dover, Jeffrey S. , Fathizadeh, Sam, Esteves, Sara C., Goldberg, Gerald N., Hoss, Elika, Ibrahimi, Omar A. , Jalian, H. Ray, Kelly, Kristen M. , Munavalli, Girish Gilly , Pozner, Jason N. , Robb, Christopher W. , Saedi, Nazanin, Shumaker, Peter R. , Stankiewicz, Kelly, Wanner, Molly, Wu, Douglas C. , Wulkan, Adam J., Ortiz, Arisa , Ross, Edward Victor , Alexiades, Macrene , Chan, Henry H L , Fathizadeh, Sam , Kelly, Kristen M , Manuskiatti, Woraphong , Munavalli, Girish S , Robb, Chris W , Wong, Brian J. F. , Bhatia, Ashish C. , ESTEVES, SARA C., Gold, Michael H , Hædersdal, Merete , Marks, Lisa , Rossi, Anthony M.

Mayo Clinic

Lasers in Surgery and Medicine | June 11, 2025 | Volume: 57 | Issue: 6 | Pages: 477-489

10.1002/lsm.70035 | PMID 40495549 Get It

ABSTRACTObjectivesTo achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and MethodsDelphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).ResultsTwo rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).ConclusionAn international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
Independent and Incremental Value of ECG Markers for Prediction of Cancer Therapy‐Related Cardiac Dysfunction
Ibtida, Ishmam, Ma, Xiaoyue , Al‐Sadawi, Mohammed , Kosmidou, Ioanna , Herrmann, Joerg , Liu, Jennifer E. , Okin, Peter M., Yu, Anthony F.

Mayo Clinic

Journal of the American Heart Association | April 17, 2025 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/jaha.124.039203 | PMID 40240957 Get It

Background Strategies to estimate risk of cancer therapy‐related cardiac dysfunction (CTRCD) before initiating cardiotoxic cancer treatment are needed. We hypothesized that baseline ECG markers could identify patients at risk for CTRCD. Methods and Results In this retrospective cohort study, 1278 female patients with stage I–III HER2 (human epidermal growth factor receptor 2)‐positive breast cancer meeting the following inclusion criteria were included: baseline ECG with QRS <120 milliseconds, baseline echocardiogram, and ≥1 follow‐up echocardiogram. Quantitative measurements of ECG waveform parameters were performed using MUSE (GE Healthcare). The primary outcome of interest was CTRCD at 1 year, defined by left ventricular ejection fraction decline (≥10% to <53% or ≥16% from baseline), or clinical heart failure (New York Heart Association class III/IV). Mean age was 51.7±11.1 years, 990 (77%) received anthracyclines, and all received HER2‐targeted therapy. CTRCD occurred in 160 (13%) patients. In a multivariable Cox proportional hazards model adjusting for our previously published CTRCD risk score (composed of patient and treatment‐specific factors), 4 ECG markers remained independently associated with CTRCD risk: QRS axis, R‐wave duration (lead II), ST segment deviation (lead II), and Sokolow–Lyon voltage (all P <0.05). Compared with a model using only clinical CTRCD risk variables, addition of ECG parameters provided incremental value for predicting CTRCD risk ( P <0.001, likelihood ratio test) with continuous net reclassification improvement of 34.9% and integrated discrimination improvement of 3.4%. Conclusions Baseline ECG variables are predictive of subsequent CTRCD and provide incremental value to established clinical risk factors for CTRCD risk classification.
P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
Cohen, Jonathon B. , Eyre, Toby A. , Woyach, Jennifer A. , Seymour, John F. , Wang, Michael , Loubert, Angély , Hess, Lisa M. , Abada, Paolo, Mato, Anthony R. , Roeker, Lindsey E. , Cheah, Chan Y. , Patel, Krish , Wang, Yucai , Payakachat, Nalin , Ghia, Paolo

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e34270c5

10.1097/01.hs9.0000971344.34270.c5 Get It

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Eyre, Toby A. , Cheah, Chan Y. , Ujjani, Chaitra S. , Koh, Youngil , Izutsu, Koji , Gerson, James N. , Flinn, Ian W. , Alencar, Alvaro J. , Ma, Shuo , Lewis, David , Patel, Krish , Maddocks, Kami J. , Lamanna, Nicole , Nagai, Hirokazu, Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Fenske, Timothy S. , Seymour, John F. , Nair, Binoj C., Tsai, Donald E. , Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao , Zhao, Junjie, Mato, Anthony R. , Shah, Nirav N. , Wang, Michael L , Flinn, Ian W , Tessoulin, Benoit , Alencar, Alvaro J , Ma, Shuo , Lewis, David , Lech-Maranda, Ewa , Rhodes, Joanna , Patel, Krish , Lamanna, Nicole , Wang, Yucai , Tam, Constantine S , Munir, Talha , Kumar, Anita , Fenske, Timothy S , Seymour, John F , Zelenetz, Andrew D , Abada, Paolo , Mato, Anthony , Shah, Nirav N , Zinzani, Pier Luigi , Cheah, Chan Yoon , Izutsu, Koji , Jurczak, Wojciech , Lech‐Marańda, Ewa , Rhodes, Joanna , Wang, Yucai , Tam, Constantine S. , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 24 | Pages: 3988-3997

10.1200/jco.23.00562 | PMID 37192437 Get It

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Chanan‐Khan, Asher , Davis, Randall S. , Eradat, Herbert, Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Hill, Brian T. , Kaesberg, Paul, Kaplan, Lawrence D. , Ma, Shuo , Mato, Anthony, Mosse, Claudio A. , Stephens, Deborah M. , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Ye, J Christine, Dwyer, Mary A., Sundar, Hema, Chanan-Khan, Asher A., Stephens, Deborah M , Ma, Shuo , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Coutré, Steven , Ghobadi, Armin , Kamdar, Manali , Khan, Nadia , Kipps, Thomas J. , Schuster, Stephen J. , Siddiqi, Tanya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 622-634

10.6004/jnccn.2022.0031 | PMID 35714675 Get It

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.